Close Menu
Home › Oncgnostics Licenses Epigenetics-Based Cervical Cancer Test to Chinese Firm

Oncgnostics Licenses Epigenetics-Based Cervical Cancer Test to Chinese Firm

Apr 11, 2017

NEW YORK (GenomeWeb) – Oncgnostics, a Jena, Germany-based molecular diagnostic company, has out-licensed its GynTect cervical cancer test to Changchun Jienuo Medical Technology (CJMT), a subsidiary of Sinopharm Group in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Featured Webinar

Development of a Novel Multiplex Assay: A Partnership Case Study

Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

What's Popular?

In PCR

  1. Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

  2. PredictImmune Inks Multinational Commercialization Pact for IBD Test

  3. British Startup Biofidelity Eyes Targeted Therapy Space With Novel Reagents

    Premium

  4. Roche Gets CE Mark for Adenovirus Transplant Monitoring Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.